411221-53-9

Usage

Uses

Used in Pharmaceutical Industry:
3-Hydroxy CitalopraM is used as an impurity in the production of Citalopram (C505000) for its role in the development and manufacturing process of the antidepressant medication. Understanding the presence and effects of this impurity can help improve the quality, safety, and efficacy of the final drug product.
Additionally, due to its unique chemical structure, 3-Hydroxy CitalopraM may have potential applications in various fields, such as:
1. Research and Development:
3-Hydroxy CitalopraM can be used as a research compound to study its pharmacological properties and potential interactions with other substances. This may lead to the discovery of new therapeutic applications or the development of novel drug delivery systems.
2. Quality Control and Analysis:
As an impurity in the production of Citalopram, 3-Hydroxy CitalopraM can be used for quality control and analysis purposes. Monitoring its presence and concentration in the final product can help ensure the safety and efficacy of the antidepressant medication.
3. Drug Interaction Studies:
3-Hydroxy CitalopraM may be used in drug interaction studies to evaluate its potential effects when combined with other medications. This can provide valuable information on the safety and efficacy of combined therapies, as well as potential side effects or contraindications.

Upstream product

• 372941-54-3 3-oxocitalopram 
• 448-59-9 tris(4-fluorophenyl)boroxine 
• 190956-77-5 4-chloro-1-(2,4-dichlorophenyl)butan-1-one 

Relevant academic research and scientific papers

Preparation method of citalopram impurities

The invention relates to a preparation method of a citalopram impurity. The preparation method comprises the following steps: oxidizing free 4-[4-(dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl]-3-hydroxybutyl]-3-hydroxymethyl benzonitrile hydrobromide and a Jones reagent to prepare a citalopram impurity C; and carrying out a reduction reaction with DIBAL-H by using the citalopram impurity C asa raw material to prepare a citalopram impurity B, wherein the citalopram impurity B is 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-3-hydroxy-1,3-dihydro-5-nitrile isobenzofuran. According to the invention, the citalopram impurity can be stably obtained at high yield, so that a basis is provided for qualitative and quantitative determination of the impurity in a raw material medicine synthesisprocess.

CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES

A chemoselective and reactive Mn(CF3-PDP) catalyst system that enables for the first time the strategic advantages of late-stage aliphatic C—H hydroxylation to be leveraged in aromatic compounds. This discovery will benefit small molecule therapeutics by enabling the rapid diversification of aromatic drugs and natural products and identification of their metabolites.

Chemoselective methylene oxidation in aromatic molecules

Despite significant progress in the development of site-selective aliphatic C–H oxidations over the past decade, the ability to oxidize strong methylene C–H bonds in the presence of more oxidatively labile aromatic functionalities remains a major unsolved

Synthesis method of aryl alcohol compound and Escitalopram

The invention discloses a synthesis method of an aryl alcohol compound and Escitalopram. The synthesis method of the aryl alcohol compound comprises the following steps: under gas protection and in an organic solvent and in the presence of transition metal, diphosphine ligand and alkali, the compound of formula 1 reacts with an aryl boron reagent 2. The synthesis method of Escitalopram comprises the following steps: (1) under gas protection and in an organic solvent and in the presence of transition metal, diphosphine ligand and alkali, the compound of formula 4 reacts with the aryl boron reagent 2; (2) under gas protection and in an organic solvent and in the presence of alkali, the compound of formula 5 reacts with dimethylamine or hydrochloride thereof; (3) under gas protection and in an organic solvent and in the presence of organic phosphine ligand and a palladium catalyst, the compound of formula 7 reacts with metal cyanide; and (4) under gas protection and in an organic solvent and in the presence of a reducing agent, the compound of formula 6 reacts. The synthesis method disclosed by the invention has high yield and enantioselectivity.